WARSAW, Ind., April 23 /PRNewswire-FirstCall/ -- Symmetry Medical Inc. (NYSE: SMA), a leading independent provider of products to the global orthopedic device industry and other medical markets, reported today financial results for fiscal year 2007. The Company has filed its Annual Report on Form 10-K with the Securities and Exchange Commission reflecting the restatement of previously issued consolidated financial statements for the 2005 and 2006 fiscal years including selected financial data for the 2003, 2004, 2005 and 2006 fiscal years. The Company has also filed amended Quarterly Reports on Form 10-QA for the first and second quarters of fiscal 2007 and its delayed Quarterly Report on Form 10-Q for third quarter of fiscal 2007.
Full Year 2007 Financial Results
The Company reported full year 2007 revenue of $290.9 million, an 18.7% increase from restated full year 2006 total revenue of $245.0 million. The Company's full year revenue included $11.3 million from Clamonta, Ltd., which was acquired by the Company on January 9, 2007, $4.7 million from TNCO Inc., which was acquired on April 3, 2007, and $7.5 million from Specialty Surgical Instrumentation Inc., which was acquired on August 31, 2007.
Gross profit for the full year 2007 was $52.6 million, a 6.8% decrease from restated full year 2006 gross profit of $56.4 million. Gross margin for the full year 2007 was 18.1%, compared to restated full year 2006 gross margin of 23.0%. Full year 2007 gross margin was negatively impacted by operational issues and other expenses at the Company's Sheffield UK facility, including extreme flooding in Sheffield and the surrounding areas in June of 2007, a lower percentage of large projects in the Company's core business and increased fixed costs associated with capacity expansion in prior years.
Selling, general and administrative expenses were $39.5 million for the total year 2007, compared with restated full year 2006 of $28.3 million. The year-over-year increase was primarily driven by the inclusion of $6.5 million of expense from the acquisitions and $3.5 million in professional fees and expenses incurred in connection with the review of accounting irregularities at the Sheffield, UK operating unit and related restatements.
The Company's effective tax rate in fiscal 2007 was significantly impacted by a valuation allowance on the net operating loss carry-forward at our Sheffield, UK operating unit of $1.8 million and a $1.4 million reserve for prior year tax positions.
Net loss for total year 2007 was $0.1 million, or $(0.00) per diluted share, compared to restated full year 2006 net income of $18.5 million, or $0.53 per diluted share.
The Company had total cash and cash equivalents of $12.1 million at December 31, 2007, compared to $11.7 million at December 31, 2006.
Brian Moore, President and Chief Executive Officer, stated, "Our restated financial statements represent the completion of a significant undertaking. While I am pleased that the restatements were solely restricted to the Sheffield, UK operating unit, the accounting review and investigation has been a long and arduous task. We have come out of the process a stronger company, with new management in Europe as well as enhanced controls. Throughout all of this, we worked hard to maintain our excellent customer service and continued to deliver quality product and a high standard of service consistent with Symmetry's reputation. We will continue to deliver the quality and service expected by our customers, supported by the tighter controls necessary to manage a growing global business."
Mr. Moore continued, "The orthopedic industry is experiencing increased product demand in 2008, which is translating for Symmetry into increased order flow for both small and large projects. In addition, the orthopedic industry is moving toward a more intensive approach to quality and regulatory issues, driven primarily by the large orthopedic implant manufacturers. In response to this trend, we will continue to build our competitive position as the quality partner that is highly responsive to our customers' requirements and specifications. We look forward to further leading the quality mandate in 2008 through our global scale and enhanced capabilities."
Symmetry has quantified the impact of the irregularities identified at its Sheffield, UK operating unit and has restated its financial statements to correct those irregularities. The restatements correct misstatements within accounts receivable, inventory, accounts payable, property, plant and equipment and the corresponding income tax and profit and loss impacts. The impact includes reduced net income of $4.8 million through January 1, 2005. Additionally, the restatement resulted in a reduction of net income in fiscal years 2005 and 2006 of $8.1 million and $5.6 million, respectively. Finally, approximately $8.2 million of the restatement relates to the period prior to the acquisition of the Sheffield, UK operating unit in June 2003. Therefore, this adjustment is reflected as a change to the opening balance sheet related to that acquisition and increases goodwill by approximately $8.2 million.
Furthermore, because the restatement reduced our operating results during these periods, our 2005 impairment test indicated the carrying value of the goodwill and intangible asset exceeded fair value. Consequently, we recorded a $33.6 million non-cash impairment charge to write off the goodwill and an intangible asset in the 2005 restated results related to the Sheffield operating unit.
On April 14, 2008, Symmetry notified its lenders that the filing of its 2007 Annual Report on Form 10-K would be extended beyond the lender's April 14, 2008 target date. The Company's lenders informed the Company that an event of default occurred due to these circumstances. While the lenders had the right to accelerate the financial obligations of the Company under the Credit Agreement, they did not exercise this right.
On April 22, 2008, the Company and its lenders entered into a Third Amendment and Waiver to Amended and Restated Credit Agreement for the purpose of waiving the described default.
The expenses incurred for outside assistance relating to the investigation and restatement process included in 2007 results are approximately $3.5 million. The Company expects these expenses in 2008 to be approximately $3.0 million.
The following estimates regarding 2008 earnings guidance are based on current market conditions and foreign currency comparisons and are forward-looking. Actual results may differ materially, and we refer you to forward-looking statements appearing at the end of the release.
For the full year 2008, the Company reconfirmed its expected revenue to be in the range of $350 million to $360 million.
Symmetry Medical will host a conference call at 8:00 a.m. ET on April 24, 2008. A live Web cast of the conference call will be available online from the investor relations page of the Company's corporate Web site at www.symmetrymedical.com. The dial-in numbers are (866) 578-5784 for domestic callers and 617-213-8056 for international callers. The reservation number for both is 68475811. After the live Web cast, the call will remain available on Symmetry Medical's Web site through July 23, 2008. In addition, a telephonic replay of the call will be available until April 30, 2008. The replay dial-in numbers are (888) 286-8010 for domestic callers and 617-801-6888 for international callers. Please use reservation code 29270896.
About Symmetry Medical Inc.
Symmetry Medical Inc. is a leading independent provider of implants and related instruments and cases to the orthopedic device industry. The Company also designs, develops and produces these products for companies in other segments of the medical device market, including arthroscopy, dental, laparoscopy, osteobiologic and endoscopy sectors and provides limited specialized products and services to non-healthcare markets, such as the aerospace market.
Statements in the press release regarding Symmetry Medical Inc.'s business, which are not historical facts, may be "forward-looking statements" that involve risks and uncertainties, within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are predictive in nature and are frequently identified by the use of terms such as "may," "might," "will," "should," "expect," "believe," "anticipate," "plan," "estimate," "intend," and similar words indicating possible future expectations, events or actions. Such predictive statements are not guarantees of future performance, and actual outcomes and results could differ materially from our current expectations. We refer you to the "Risk Factors" and "Forward Looking Statements" sections in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission as well as the Company's other filings with the SEC, which are available on the SEC's Web site at www.sec.gov.
SOURCE Symmetry Medical Inc.